Table 2.
Treatment-emergent adverse events reported in ≥10% of patients
| Any grade, n (%) | Drug-related grade ≥3, n (%) | |
|---|---|---|
| Blood and lymphatic system disorders | ||
| Anemia | 12 (40) | |
| INR increased | 5 (17) | |
| Lymphopenia | 11 (37) | |
| Neutropenia | 6 (20) | |
| Thrombocytopenia | 13 (43) | 7 (23) |
| Prolonged aPTT | 3 (10) | |
| Leukopenia | 9 (30) | 3 (10) |
| Cardiovascular | ||
| Hypertension | 6 (20) | |
| ENMT | ||
| Xerostomia | 6 (20) | |
| Gastrointestinal | ||
| Abdominal pain | 5 (17) | |
| Anorexia | 3 (10) | |
| Elevated alkaline phosphatase | 10 (33) | |
| Elevated alanine aminotransferase | 8 (27) | |
| Elevated aspartate aminotransferase | 6 (20) | |
| Hyperbilirubinemia | 8 (27) | |
| Nausea | 3 (10) | |
| Vomiting | 6 (20) | |
| Weight gain | 3 (10) | |
| Weight loss | 3 (10) | |
| General | ||
| Chills | 3 (10) | |
| Edema limbs | 4 (13) | |
| Xeropthalmia | 4 (13) | |
| Fatigue | 5 (17) | |
| Fever | 4 (13) | |
| Noncardiac chest pain | 3 (10) | |
| Infection | ||
| Catheter-related infection | 3 (10) | |
| Sepsis | 3 (10) | |
| Metabolic | ||
| Hyperkalemia | 6 (20) | |
| Hyperglycemia | 11 (37) | |
| Hypermagnesemia | 5 (17) | |
| Hypernatremia | 4 (13) | |
| Hypertriglyceridemia | 5 (17) | |
| Hypoalbuminemia | 10 (33) | |
| Hypocalcemia | 8 (27) | |
| Hypoglycemia | 6 (20) | |
| Hypokalemia | 15 (50) | |
| Hypomagnesemia | 10 (33) | |
| Hyponatremia | 9 (30) | |
| Hypophosphatemia | 10 (33) | |
| Musculoskeletal | ||
| Generalized muscle weakness | 7 (23) | |
| Nervous system disorder | ||
| Dizziness | 5 (17) | |
| Dysgeusia | 3 (10) | |
| Tremor | 3 (10) | |
| Psychiatric disorders | ||
| Anxiety | 4 (13) | |
| Insomnia | 7 (23) | |
| Respiratory | ||
| Cough | 3 (10) | |
| Dyspnea | 5 (17) | |
| Epistaxis | 3 (10) | |
| Other | ||
| Pruritus | 5 (17) | |
| Xerosis | 7 (23) |
aPTT, activated partial thromboplastin time; ENMT, ear, nose, mouth, and throat; INR, international normalized ratio.